NTLA (Intellia Therapeutics) Ending Cash Position: $121.53 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NTLA Intellia Therapeutics Inc NTLA
70 GF Score
Price $11.91
GF Value $13.81
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Intellia Therapeutics Ending Cash Position?

Intellia Therapeutics NTLA +0.76% 70 Ending Cash Position is $121.53 Mil as of Jun. 2026. GuruFocus rates NTLA with a GF Score™ of 70/100 and a GF Value™ of $13.81 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Intellia Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was $121.53 Mil.

Intellia Therapeutics's quarterly Ending Cash Position declined from Dec. 2025 ($167.57 Mil) to Mar. 2026 ($150.10 Mil) and declined from Mar. 2026 ($150.10 Mil) to Jun. 2026 ($121.53 Mil).

Intellia Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($240.35 Mil) to Dec. 2024 ($202.79 Mil) and declined from Dec. 2024 ($202.79 Mil) to Dec. 2025 ($167.57 Mil).

Intellia Therapeutics Ending Cash Position Related Terms

Intellia Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Ending Cash Position Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 125.49 535.46 240.35 202.79 167.57

Intellia Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 170.13 207.34 167.57 150.10 121.53
NTLA
70GF Score
Intellia Therapeutics Inc NTLA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Intellia Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=202.787+-35.219
=167.57

Intellia Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=150.101+-28.569
=121.53

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $121.53 Mil mean?
Intellia Therapeutics (NTLA) has a Ending Cash Position of $121.53 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Intellia Therapeutics and its competitors.
Is Intellia Therapeutics' Ending Cash Position too high?
Intellia Therapeutics' current Ending Cash Position is $121.53 Mil. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Ending Cash Position compare to SEPN and AVBP?
Intellia Therapeutics' Ending Cash Position of $121.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Ending Cash Position is $121.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.81, compared to a current price of $11.91 — trading 13.8% below its estimated fair value. The current Ending Cash Position is $121.53 Mil. Intellia Therapeutics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Ending Cash Position is $121.53 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $11.91 is trading 13.8% below its estimated GF Value™ of $13.81. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for NTLA:

  • Ending Cash Position: $121.53 Mil
  • GF Value™: $13.81 vs. price of $11.91 (13.8% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Other Exchanges 0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score

Get the complete analysis for NTLA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.91
Price
$13.81
GF Value